So to the issues that were raised, I think the two really important things are that this isn't going to be mandated—that was very clear to the select committee—and the application would be required if the assay changes, although I note that assay is only one aspect of dose management. There's also the frequency and quantum of the dose that's administered in any pharmaceutical. I doubt that that will be amended, but technically it could be. 